We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A higher likely risk for mortality in COVID-19 patients ...
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
Global Arterial Cannula Market OverviewThe global arterial cannula market is witnessing steady expansion and is projected to grow at a CAGR of approximately 7% during the forecast period, supported by ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. U.S. hospitalizations requiring ECMO totaled $908 ...
HONOLULU -- In hindsight, researchers saw more limitations to extracorporeal membrane oxygenation (ECMO) and proning, therapies initially touted as helpful for COVID patients in intensive care.
Use of left atrial venoarterial cannulation during extracorporeal membrane oxygenation—a technique known as LAVA ECMO—appears to be a safe and feasible means of support for patients with cardiogenic ...
Extracorporeal Membrane Oxygenation (ECMO) provides essential support for intensive care unit (ICU) patients, 60% of whom develop heart or respiratory failure with a mortality rate of 23-75%. In China ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results